BMO reiterates Scholar Rock stock rating on rival drug discontinuation By Investing.com

Genentech discontinued emugrobart, removing a key competitor and prompting BMO Capital to reiterate an Outperform rating with a $70 price target on Scholar Rock. SRRK has surged 48% over the past six months to $45.50, reported $367.6M in cash at fiscal 2025 year-end, secured a debt facility of up to $550M to support the apitegromab launch, and saw multiple analysts raise price targets (Barclays $53, Piper Sandler $58, Truist $55, JPMorgan $50) while 5 analysts revised earnings upward.

Analysis

A narrower competitive set in SMA-like indications materially shifts the commercial dynamics from a multi-player price war to a two-player negotiation between manufacturer and payers. Fewer late-stage entrants reduces the bargaining leverage of PBMs and Medicaid managers, meaning realized net price could be 200–500bps higher than a congested-market baseline; that change alone converts modest peak sales into commercially viable economics for a small-cap biologics issuer.

Operational execution — not label breadth — is the single biggest second-order determinant of value over the next 12–24 months: commercial manufacturing yield, distribution fill-rates, and real-world adherence will govern first‑year revenue ramp and cash consumption. A single failed batch, slower-than-expected fill rates, or an unanticipated safety signal can compress valuation multiples by 40–70% in weeks; conversely, clean launch metrics and early payer win stories can re-rate shares by multiple turns.

The consensus appears to underweight downside scenarios tied to payer access and longer timelines for durable uptake versus headline regulatory events. If gene therapy utilization accelerates or a lower-cost therapeutic alternative emerges within 2–4 years, the addressable population could materially shrink; investors should therefore treat any current premium as contingent on flawless commercial execution and favorable net pricing rather than solely on regulatory clearance.

Key Decisions for Investors

• Directional, asymmetric call exposure: Buy SRRK Jan 2027 $50 calls (or nearest available strike) to capture approval + early launch optionality. Max loss = premium; target 3x on approval + favorable net pricing, cut half position on >6 month regulatory delay or if first commercial fill-rate <70%.
• Equity + collar for conservative exposure: Buy SRRK shares and fund a 9–12 month protective collar by selling 1–2x short-term (3–6 month) OTM calls and buying OTM puts (strike ~30–40% below entry). This preserves upside through initial launch while limiting a catastrophic drawdown from regulatory or manufacturing failure.
• Paired trade to remove sector beta: Long SRRK equity (or calls) and short 25–35% notional of XBI (or a bespoke small-cap biotech basket) to isolate idiosyncratic approval/launch risk. Exit hedge on first commercial payer contract announcement or on FDA approval.
• Risk-managed short catalyst hedge: Buy 3–6 month puts sized at 20–30% of your long position as an inexpensive hedge against a safety/regulatory headline — aim for puts ~30–40% OTM to limit premium spend while protecting against quick, large drawdowns.